Melphalan

Melphalan works by attaching alkyl groups to the N7 position of guanine bases in DNA, creating cross‑links that block DNA replication and transcription. This interference triggers cell cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The dose of Melphalan is individualized and set by the prescribing oncologist based on the specific indication, patient weight, renal function, and treatment protocol. No standard dose is provided here; clinicians determine the appropriate regimen for each patient.

Melphalan is classified as having unknown safety in pregnancy and is considered teratogenic in animal studies. It is generally contraindicated for pregnant women, and breastfeeding is not recommended because the drug may be excreted in milk and affect the infant.

To order Melphalan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Melphalan belongs to the alkylating agent class, similar to cyclophosphamide and ifosfamide. Compared with cyclophosphamide, melphalan has a higher potency for DNA cross‑linking but also a greater risk of myelosuppression. Choice of agent depends on tumor type, prior therapy, and the treating physician’s assessment of risk‑benefit balance.

Melphalan for injection should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze the product, and handle it using appropriate protective equipment such as gloves and a biological safety cabinet to avoid accidental exposure.

Melphalan is administered intravenously by a qualified healthcare professional. The infusion rate and duration are determined by the treatment protocol and patient tolerance, and the drug is typically given in a controlled clinical setting with monitoring for immediate adverse reactions.

The most serious risks include severe neutropenia, which can lead to life‑threatening infections; thrombocytopenia, increasing bleeding risk; and the rare possibility of secondary malignancies developing years after treatment. Patients should be monitored closely for signs of infection, bleeding, and unexpected symptoms.

Melphalan should not be used in patients with known hypersensitivity to the drug, in pregnant or nursing women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant renal impairment or those receiving other myelosuppressive therapies.